ライフサイエンスコーパス: baseline value

1 ints and >50%) or full (LVEF increase to the baseline value).

2 nse (platelet count >/=30 x 10(9)/L and >/=2 baseline value).

3 justment for study, treatment, and the above baseline values).

4 allocated to treatment groups, adjusted for baseline value.

5 ilation was lowered to less than half of its baseline value.

6 e, GDM decreased to approximately 50% of the baseline value.

7 psilateral to the hematoma compared with the baseline value.

8 1 month of treatment (M1) compared with the baseline value.

9 ce values for each subject to that patient's baseline value.

10 cantly reduced when compared to pre-ischemia baseline values.

11 cantly larger in most patients compared with baseline values.

12 of the subjects studied before returning to baseline values.

13 een arms in Ki-67 after 4 weeks adjusted for baseline values.

14 ysis of covariance model with adjustment for baseline values.

15 y restored transition probabilities to their baseline values.

16 ding, lower-body fat had not yet returned to baseline values.

17 flow velocity in response to Ach relative to baseline values.

18 eekly until it decreased to less than 20% of baseline values.

19 rovided this was at least a 50% decline from baseline values.

20 ; and ICP (+3.6 +/- 0.7 mm Hg) compared with baseline values.

21 ell subsets), but usually did not recover to baseline values.

22 ine control teeth) were compared to original baseline values.

23 ars, particularly for patients with abnormal baseline values.

24 ht ventricular stem cell expressions to near baseline values.

25 d by 439+/-493 ml (P=0.02), as compared with baseline values.

26 nded area reduced food intake by 42.3% below baseline values.

27 tiation of rilonacept and were compared with baseline values.

28 ult, they hold all other parameters fixed at baseline values.

29 analysis of covariance adjusting for subject baseline values.

30 that ranged between 52 and 141% higher than baseline values.

31 after vector infusion and were compared with baseline values.

32 ds dropped to as low as approximately 10% of baseline values.

33 s were performed until perfusion returned to baseline values.

34 ion was seen after 2 min of US compared with baseline values.

35 and taurine levels declined significantly to baseline values.

36 fter the extraction, all markers returned to baseline values.

37 t different time points after injection with baseline values.

38 % versus 33+/-5%, respectively; P<0.0001) or baseline values.

39 surement period for either group compared to baseline values.

40 cle reinnervation and reportedly exceed 140% baseline values.

41 were slightly accelerated relative to their baseline values.

42 CCB did not alter PAP or PVR/SVR from baseline values.

43 the proportion of collagen III was 70% above baseline values.

44 tivity at postcoital visits were compared to baseline values.

45 ictive of survival time after adjustment for baseline values.

46 e of survival time even after adjustment for baseline values.

47 sistance (CVR = MAP/CBF) and MAP relative to baseline values.

48 s were significantly decreased compared with baseline values.

49 post procedure >/=0.5 mg/dL or >/=25% above baseline values.

50 e and not confined to those with the highest baseline values.

51 volume and decreased laterality index versus baseline values.

52 ) at 3 months after surgery, compared to the baseline values.

53 th risk factors for CVD after accounting for baseline values.

54 gery decreased over time by 6% to 28% of the baseline values.

55 cessful resuscitation when compared with the baseline values.

56 nths and 5 years were compared with original baseline values.

57 HbA1c levels were evaluated and compared to baseline values.

58 nce decreased by 1.5 miles/day compared with baseline values (-1.5 +/- 1.7 miles/day; P = 0.0005).

59 Thereafter, either CO2 (PaCO2 = baseline value + 10 mm Hg) or N2 (PaO2 = 45-55 mm Hg) wa

60 re not or were imputed conservatively to the baseline value (13.3% vs 5.3%, 95% CI for the estimated

61 cantly increased at follow-up as compared to baseline values (2.0 +/- 0.52 mm vs. 2.25 +/- 0.50 mm, 1

62 htly increased, but was still lower than the baseline value (215 mum, 255 mum, and 299 mum during the

63 alculate hazard ratios (HRs) per 1 SD higher baseline values (4.56 kg/m(2) higher BMI, 12.6 cm higher

64 l4-treated mice (18.3 +/- 6.5) compared with baseline values (5.2 +/- 1.0).

65 7 treated arteries, NEPI levels remained at baseline values (620 to 991 ng/g), </=20% of the nerves

66 observed at 36 months in comparison with the baseline value (77.9 +/- 10.0 ETDRS letters, P = .22).

67 r scar size at 3 months after correcting for baseline values (95% CI, -1.33 to -0.32 mm; P = .001) in

68 over the subsequent months, returning to the baseline value after 1 year.

69 ime required for the NAP to reach 50% of its baseline value after recovery from hypoxia and the NAP a

70 res and fixed-covariate Cox models with only baseline values after controlling for important clinical

71 2% to -17.6+/-1.6%, P<0.001) and returned to baseline values after delivery (-19.5+/-2%).

72 3-93.1 mL/m(2); P=0.028) but was reversed to baseline values after hTPV implantation (to 65.1 mL/m(2)

73 telet effects with 150 mg, which returned to baseline values after resumption of standard dosing.

74 triphasic viral decay and a viral rebound to baseline values after the cessation of therapy.

75 ehavioral state changes returned to control (baseline) values after the cessation of antisense admini

76 th more accurate prognostic information than baseline values alone.

77 ar sensitivity was found to shift toward the baseline value, although the return to baseline was not

78 to trophic level), as well as differences in baseline values among the regions in which sharks forage

79 in vitro inotropic effect up to 283% of the baseline value and increased the rates of contraction an

80 The median (interquartile range) baseline value and mean+/-SD annual change of CLurea wer

81 the plasma clearance of iohexol) between the baseline value and the last available value during the f

82 Both the baseline value and the rapidity in change of the value o

83 P-IR had declined in all layers by 30-39% of baseline values and by 8 weeks had returned to control v

84 c mean titers and fold increases relative to baseline values and by comparing changes in the seroconv

85 After adjusting for baseline values and center effect, there was a 21% diffe

86 relation of the number of exacerbations with baseline values and changes in PFTs and CT scores.

87 using mixed-effects models, controlling for baseline values and clustering within practices.

88 0.02) after adjustment for the corresponding baseline values and for several confounding factors asso

89 oup analyses regarding QOL were adjusted for baseline values and gender.

90 morotibial cartilage composition, we studied baseline values and one-year change in superficial and d

91 intention-to-treat basis with adjustment for baseline values and other relevant clinical variables.

92 ens insertion, all variables had returned to baseline values and remained that way for at least 4 hou

93 olute differences relative to the average of baseline values and repeatability analysis were performe

94 n were significantly lower (P <.01) than all baseline values and than the follow-up values in the con

95 The analyses showed that after baseline values and time-dependent confounders were cont

96 (nondisplaceable binding potential) between baseline values and values following methylphenidate inj

97 TE was performed after overnight fasting (baseline values) and 15, 30, 45, 60, 90, and 120 min fol

98 t chains (dFLC) of >20 mg/L, a level >20% of baseline value, and a >50% increase from the value reach

99 Hypothalamic signals were normalized to baseline value, and differences between the pre- and pos

100 g the follow-up period, in percentage of the baseline value, and the incidence of obesity during the

101 ne value, the FVC was 346+/-712 ml above the baseline value, and the residual volume was 333+/-570 ml

102 Arterial pressure did not increase above baseline values, and systemic vascular resistance was un

103 ANCOVA and mixed linear models with sex and baseline value as covariates.

104 a within factor (repeated) of visit, and the baseline value, as well as age and gender, as covariates

105 postoperatively (P </= 0.01) with return to baseline values at 12 months postoperatively (P = 0.57).

106 uximab group, but levels increased to 69% of baseline values at 12 months.

107 tly at 1 hour (P = 0.031), returning back to baseline values at 2 hours.

108 , were significantly decreased compared with baseline values at 6 months, and the levels became simil

109 NFD approximated baseline values at 6 weeks and did not change any furthe

110 es decreased to 60 +/- 40% and 83 +/- 93% of baseline values at 6-8 months and at 10-14 months, respe

111 anti-dsDNA antibodies fell to 42 +/- 36% of baseline values at 6-8 months and to 37 +/- 33% at 10-14

112 creatinine concentration was unchanged from baseline values at 9 and 24 months.

113 ion in L4 and L5 DRG followed by a return to baseline values at later stages following injury.

114 as assessed by FEV1, as compared with their baseline values at the start of azithromycin therapy.

115 Compared with baseline values, atorvastatin reduced apoB-100 (-33%), t

116 sulinemic hypoglycemia by 0.36 U (14%) below baseline values (B coefficient, -0.36; 95% confidence in

117 After adjustment for baseline values, back-related function in the yoga group

118 sue is reduced quickly to less than half its baseline value before the creatine phosphate (CrP) pool

119 o the hematoma, ranging from 134% to 187% of baseline value between 1 and 5 hrs after hematoma creati

120 The difference in baseline values between groups was also examined.

121 res to adjust for the imbalance in covariate baseline values between these two groups.

122 Cardiac output recovered to the baseline value by 5 mins post-RM in oleic acid injury an

123 as reduced if 48-hour urine volumes exceeded baseline values by >/= 10%.

124 therapy, the mean viral loads decreased from baseline values by 0.07 log(10) copies/mL in the placebo

125 ts, cramping, and bleeding returned close to baseline values by 1 year.

126 of 521 nmol/L at 1 d and then a fall to near-baseline values by 7-14 d.

127 is rates decreased by day 3 but recovered to baseline values by day 10.

128 ting CD4(+) T-cell counts, which returned to baseline values by day 30 in 26 of 30 evaluable patients

129 All parameters returned to baseline values by month 12 and remained so at month 36

130 ined at the follow-up were compared with the baseline values by using parametric or nonparametric tes

131 Assigning baseline values carried forward to the 22% of patients w

132 e residual volume was 333+/-570 ml below the baseline value; cerebral lesions were unchanged.

133 ls decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [CI, -0.27 to -0.0

134 Fgf2 knockout hearts recovered to 27% of its baseline value compared with a 63% recovery in wild-type

135 Despite restored heart rate and MAP to baseline values, CR animals developed a progressive inte

136 erfusion due to occlusion (from preocclusion baseline values) (%DECREASE) and the maximum increase (f

137 After adjusting for baseline value, demographics, depression, and mental sta

138 d glutamate/GABA concentrations recovered to baseline values during a subsequent muscle contraction.

139 increased at the time of AAD and returned to baseline values during follow-up for these patients with

140 pendent manner, with levels returning toward baseline values during followup.

141 3 mmHg; P < 0.05) and heart rate returned to baseline values during PEMI (83 +/- 3 to 67 +/- 2 beats

142 At HA, OCI returned almost immediately to baseline values during recovery, whereas at SL it remain

143 constriction, as both HABF and HAVR remained baseline values during the endotoxic phase (P < 0.05 vs.

144 he return of the discharge creatinine to the baseline value, experienced a significant decrease in th

145 ient increase in the frequency of Tregs from baseline values following acute infection in RM, but no

146 Elevated GABA+ concentrations returned to baseline values following drug clearance.

147 elevated numbers before returning to normal baseline values following intranasal OVA exposure.

148 The mean delta over baseline value for a negative diagnosis was 1.03 +/- 0.8

149 The efficacy population of 47 patients had a baseline value for anti-factor Xa activity of at least 7

150 baseline body mass index, weight change, and baseline value for respective outcomes (P-interaction =

151 The average baseline value for the primary outcome, the attention an

152 increases in the FEV1 at M1 relative to the baseline value for the treated and placebo groups were 1

153 tcome required at least 20% improvement from baseline values for at least 2 of the following 3 domain

154 ly improved prognostic discrimination beyond baseline values for fatal outcomes only.

155 Lower baseline values for FEV1, smaller bronchodilator respons

156 to compare QoL at 3, 6, 18, and 36 months to baseline values for patients categorized into 2 groups:

157 Baseline values for reader performance with screen-film

158 d sex, ethnicity, age, disease duration, and baseline values for rheumatoid factor and the tender and

159 Baseline values for the chemokine CXCL16 was an independ

160 neumococcal meningitis were assessed against baseline values from 1998-1999.

161 NP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1 an

162 equal or greater than 3 logs compared with a baseline value have a significantly better progression-f

163 Baseline values have also been shown to be prognostic in

164 ter treatment, there was no improvement from baseline values (i.e., reduction) in wall motion score (

165 in the temperature greater than the diurnal baseline values identified the onset of the systemic res

166 se in serum creatinine level from the stable baseline value in <6 months or an increase of >/= 0.3 mg

167 on rate (GFR) to </=60 mL/min or to half the baseline value in subjects who entered with GFR <120 mL/

168 the occlusion and remains within 30% of its baseline value in vessels as far as 10 branch points dow

169 de 3: n = 1) but creatinine/eGFR returned to baseline values in all patients.

170 Serum cytokine concentrations returned to baseline values in both groups by 24 hrs.

171 Despite near-normal mean baseline values in FEV1, patients receiving ivacaftor ha

172 aminotransferase at week 12 compared to the baseline values in LAL-CL01 were 46 +/- 21 U/L (-52%) an

173 as variability over time) over and above the baseline values in logistic regression models.

174 -up, HOMA2-IR and BMI levels returned toward baseline values in patients who did not respond or relap

175 OVB, there were significant reductions from baseline values in proximal (P=.002), mid (P=.0003), and

176 Whereas the number of NK cells returned to baseline values in the blood, the GI tissues remained de

177 ported significantly less pain compared with baseline values in the final week of treatment than did

178 and should provide explicit estimates of the baseline values in the original data space for optimal d

179 tions performed in the same rats and between baseline values in treated and control rats, respectivel

180 vely stable (composite end point relative to baseline values) in >/=85% of patients as well as indivi

181 statistically significant improvements from baseline values, including wKT in the EMD group, which a

182 whose galectin-3 stayed within +/-15% of the baseline value, independent of age, sex, diabetes mellit

183 nergic stimulation than those who had better baseline values, indicating that a cholinergic deficit c

184 ractitioner could input a patient's relevant baseline values into a handheld computer programmed with

185 decrease in cell stiffness back towards the baseline value is consistent with a replacement of the o

186 The changing baseline values lead to potential compliance challenges

187 mean diffusivity (MD) was unchanged despite baseline values lower than controls (p < 0.05), and frac

188 As baseline values may have impact on the treatment respons

189 10 mg/kg/d deferasirox groups, respectively (baseline values [means +/- SD], 13.11 +/- 7.29 and 14.56

190 ed, NADH fluorescence and Psi(m) returned to baseline values much faster than mitochondrial [Ca2+].

191 Improvement in renal function, compared with baseline values, occurred in 27% of recipients 1 month a

192 icantly (P = 0.0007) from a preinfusion mean baseline value of 0.27 to a mean GMI of 0.83 by 30 min t

193 he urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02).

194 acerbations, CAT scores rose from an average baseline value of 19.4 +/- 6.8 to 24.1 +/- 7.3 (P < 0.00

195 of therapy was significantly higher than the baseline value of 61 U/L.

196 ximum amplitude in TEG) was decreased from a baseline value of 72.2 +/- 1.4 mm to 56.2 +/- 3.1 mm (P

197 ty (angle alpha in TEG) was decreased from a baseline value of 73.3 +/- 1.1 degree to 63.0 +/- 2.4 de

198 with the concentration of attractant from a baseline value of 8-42 microm(2)/s at a concentration of

199 ompared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per lite

200 tivity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activ

201 ment for age, sex, smoking, BMI, season, and baseline value of each metabolic outcome variable.

202 A baseline value of LVS < 0.84 or IVS >/= 18.8 degrees pre

203 e assessed with a mixed model with terms for baseline value of the response variable, age, sex, regio

204 n, or toxic effects, stratified according to baseline value of TrPAL (</= or > the upper limit of nor

205 e in pH(o), P(CO2) and/or [NaHCO(3)](o) from baseline values of 7.4, 5 % and 26 mM, respectively.

206 , received > or =30 days of therapy, and had baseline values of absolute CD4, %CD4, and HIV-1 RNA.

207 Baseline values of all four variables were predictive of

208 was trained to predict individual risk from baseline values of cholinesterase, bilirubin, type of pr

209 p, presence of type 2 diabetes mellitus, and baseline values of each dependent variable.

210 luding 4 children (</=3 years old) to define baseline values of early life and 12 adults (>/=18 years

211 Baseline values of estradiol and estrone sulfate were si

212 Although baseline values of FLC are prognostic in newly diagnosed

213 Higher baseline values of HbA1c were associated in a graded fas

214 We aimed to 1) determine baseline values of iron and inflammatory markers in chil

215 n allocation among participants with greater baseline values of N-BNP.

216 top third with those in the bottom third of baseline values of natriuretic peptides, the combined ri

217 trial database to develop two models, using baseline values of routinely available laboratory tests

218 After adjustment for baseline values of several established risk factors, the

219 ean changes in oral status were adjusted for baseline values of smoking status, number of teeth prese

220 Replication analysis showed that baseline values of surfactant protein D (46.6 ng/mL vs 3

221 Baseline values of thermodilution cardiac output were hi

222 anges from baseline and the relation between baseline values of these variables to sustained virologi

223 ved replicate grades within two steps of the baseline value on the AREDS severity scale for temporal

224 Path analyses examined the impact of baseline values on 1-year values for each of the 4 varia

225 A for overall treatment effect, adjusted for baseline values); only the higher dose of gabapentin was

226 increase in serum creatinine >1.5 times the baseline value or a new requirement for renal replacemen

227 re no associations between systemic factors (baseline values or change from baseline) and mean change

228 agent exposure was screened and revealed no baseline values or potential interferences.

229 ered (P > 0.80) when compared with untreated baseline values or vehicle-treated control eyes.

230 uding decaying oscillations returning to the baseline value over 35-100 s, oscillations superimposed

231 s are compared relative to their diesel-only baseline values over transient and steady state testing.

232 t increase in their platelet count above the baseline value (P < or =.01) reaching the peak value (me

233 a significant increase of > or =50% over the baseline value (P <.05).

234 volume at 12 months was 53.2+/-26.6% of the baseline value (P<0.001) and at 24 months was 85.9+/-28.

235 4 weeks, that was more than eight times the baseline value (P<0.001), without affecting CD4+ convent

236 ased to a median of more than five times the baseline value (P<0.001).

237 nths, CFI was 0.14+/-0.07 or 63+/-27% of the baseline value (P<0.001).

238 01) and at 24 months was 85.9+/-28.5% of the baseline value (P=0.005).

239 and nrCBF significantly increased for higher baseline values (P < .01).

240 hout tolerance induction, when compared with baseline values (P < 0.035 and 0.02, respectively).

241 nce signal of arthritic joints compared with baseline values (P < 0.05).

242 ll groups after training compared with their baseline values (P < 0.05).

243 BOP and PD decrease and CAL gain compared to baseline values (P <0.05).

244 min observation period there was a return to baseline values (p = NS).

245 one and RYGB plus omentectomy, compared with baseline values (P<.001).

246 y bypass, MMP activity increased by 20% from baseline values (P<0.05), and then rapidly fell with car

247 e to treatment was significantly modified by baseline values (P-interaction = 0.02), with the increas

248 Compared with baseline values, patients treated with atorvastatin had

249 After analysis was controlled for baseline values, patients who underwent autologous recon

250 tenuated in both scenarios compared with the baseline values.Potential industry-wide reformulation of

251 riance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 mo

252 month to become maximal, but returned toward baseline values rapidly once rats resumed ad libitum die

253 Compared with the baseline values, RD, RW, CAL, and root surface area decr

254 the respective rates of change, with higher baseline values relating to faster reductions.

255 5% (p < 0.01) and 45 +/- 6% (p < 0.05) from baseline values, respectively, achieving near normal val

256 mean +/- SD of 64 +/- 37% and 38 +/- 33% of baseline values, respectively, by 6-8 months post-BCDT.

257 alyses for complete-cases and adjustment for baseline values showed similar results.

258 In an intent-to-treat analysis with baseline value substitution, mean weight loss was 7.4 kg

259 7.9%; 95% CI, 81.2%-94.6%) who established a baseline value that could be used as a reference for fut

260 ontinued, the FEV1 was 62+/-411 ml above the baseline value, the FVC was 346+/-712 ml above the basel

261 Compared with baseline values, the fractional synthesis rate of erythr

262 Compared with baseline values, the mean sub-basal nerve density decrea

263 As compared with baseline values, the normalized total atheroma volume sh

264 hese parameters subsequently returned toward baseline values, the observed differences between the tr

265 Compared with baselines values, the mean subbasal nerve density (P < 0

266 t 8 weeks (P<0.001 for both comparisons with baseline values), then declined when the patients were n

267 choalveolar lavage and became similar to the baseline value thereafter.

268 n increase in serum creatinine >25% from the baseline value to 30 day was significantly lower in pati

269 xpiratory volume in 1 second (FEV1) from the baseline value to the average of the week 4 and week 8 m

270 in these HIV-1-infected children moved from baseline values to about halfway to two-thirds of the wa

271 Comparing pediatric liver stiffness to adult baseline values to detect pediatric liver mechanical abn

272 rtional to tracer efflux, were compared with baseline values to determine changes in FPAC distributio

273 analysis of covariance while controlling for baseline values to examine intervention effects and cond

274 epeated measures was used, including patient baseline value, treatment, visit, and treatment-by-visit

275 14.1 +/- 5.1 to 15.9 +/- 6.8 (P<0.05), with baseline values trending higher among individuals who re

276 g water was significantly different from the baseline value until 2 hours after bronchoalveolar lavag

277 After 8 wk, with baseline values used as a covariate, no differences were

278 ) and select laboratories were compared with baseline values using nonparametric statistics.

279 increase in B-6 vitamer concentrations over baseline values was observed after 28 d of treatment wit

280 Baseline values were available in 296 patients, and of t

281 aired analyses of the differences from these baseline values were conducted by finding the mean diffe

282 However baseline values were re-established with 20 minutes.

283 After the stressor, sAA (p=0.026) baseline values were reached considerably faster in the

284 Tracheal baseline values were significantly higher in children wi

285 Daily peak serum creatinine (adjusted for baseline) values were also associated with delirium (OR,

286 R scores (adjusted for clinic site, sex, and baseline values) were not different between groups.

287 ed reduction in physical activity returns to baseline values when weight loss is maintained.

288 and PML edge markers from the MA plane from baseline values while leaflet length was obtained by sum

289 xposed group collectively approached 100% of baseline values, while that of the control group was in

290 individuals and demonstrate that individual baseline values will be essential for predicting disease

291 retinal sensitivity tests for comparison of baseline values with 6 months after surgery.

292 values >14, or 2 increases of > or = 5 from baseline values with at least one value > or = 12.

293 fore rituximab therapy, and a reduction from baseline values with rituximab therapy was observed for

294 5%) lean mass (both P < 0.0001 compared with baseline values), with no differences between 25% and 15

295 ) visceral fat (all P < 0.0001 compared with baseline values), with no differences between the diets

296 of > or = 20 mmHg in SBP compared with their baseline value, with a mean change of 20.6 mmHg (P < .00

297 serum creatinine concentration >25% from the baseline value within a 3-day period.

298 Platelet counts generally returned to baseline values within 2 weeks after the end of treatmen

299 65 g/kg at 24 h (P < 0.01) below established baseline values within 24 h without significant changes

300 ction test parameters (PFTs) return to their baseline values within a few weeks.